Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tejal A Patel

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Breast Cancer Research : BCR|September 4, 2019
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)Tejal A Patel, Joe E Ensor, Sarah L Creamer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.
Radiology. Artificial Intelligence|December 11, 2023
A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 MammogramsChika F Ezeana, Tiancheng He, Tejal A Patel, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Breast Cancer Research : BCR|September 4, 2019
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)Tejal A Patel, Joe E Ensor, Sarah L Creamer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.
Radiology. Artificial Intelligence|December 11, 2023
A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 MammogramsChika F Ezeana, Tiancheng He, Tejal A Patel, et al.
Pageof 2